Literature DB >> 29601306

Evidence-based guidelines in lower urinary tract symptoms secondary to benign prostatic hyperplasia and variation in care.

Seth A Strope1.   

Abstract

PURPOSE OF REVIEW: Guidelines have been developed to assist physicians in the diagnosis and management of patients with lower urinary tract symptoms. These guidelines vary in the level of evidence used and the strength of their recommendations. With variations in guidelines, multiple variations in clinical practice may also been seen. RECENT
FINDINGS: Although examinations of physician compliance with benign prostatic hyperplasia (BPH) guidelines date back to the 1980s, researchers have become more interested in closer examination of guideline compliance. Furthermore, guidelines themselves are becoming more robust documents, with the American Urological Association and European Association of Urology guidelines updated in 2014 and 2015, respectively. This review examines both the evidence base behind these BPH guidelines and the variations in clinical care related to the guidelines.
SUMMARY: Despite over 40 years of study, variations continue to occur in the work up and treatment of men with BPH. With the proliferation of medications and surgical procedures available for symptomatic lower urinary tract symptoms (LUTS) due to BPH, we will continue to see this variation in care. Our current guidelines can help mitigate this variation by providing a baseline set of assessments and algorithms for routine patients. However, only through continued refinement will the guidelines meet their full potential. The prior review shows how the evidence base is limited for the diagnostic work up for LUTS, provides limited information on comparative effectiveness of therapies in LUTS and BPH, and has not led to consistency between guidelines.

Entities:  

Mesh:

Year:  2018        PMID: 29601306     DOI: 10.1097/MOU.0000000000000504

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  5 in total

1.  Evaluation of the clinical pharmacist role in improving clinical outcomes in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.

Authors:  Mera Ababneh; Duaa Shamieh; Saddam Al Demour; Abeer Rababa'h
Journal:  Int J Clin Pharm       Date:  2019-09-06

2.  Non-Invasive Predictors of Response to Tamsulosin for Benign Prostatic Obstruction.

Authors:  Mohammad Shoaib; Muhibullah Bangash; Wajahat Aziz; M Hammad Ather
Journal:  Cureus       Date:  2021-02-15

3.  Effect of precise nursing service mode on postoperative urinary incontinence prevention in patients with prostate disease.

Authors:  Xi-Chun Zheng; Ting-Ting Luo; Dan-Dan Cao; Wen-Zhi Cai
Journal:  World J Clin Cases       Date:  2022-02-16       Impact factor: 1.337

4.  Reliability and validity of assessment methods available in primary care for bladder outlet obstruction and benign prostatic obstruction in men with lower urinary tract symptoms: a systematic review.

Authors:  Tom Vredeveld; Esther van Benten; Rikie E P M Beekmans; M Patrick Koops; Johannes C F Ket; Jurgen Mollema; Stephan P J Ramaekers; Jan J M Pool; Michel W Coppieters; Annelies L Pool-Goudzwaard
Journal:  BMJ Open       Date:  2022-04-29       Impact factor: 3.006

5.  High regional variation in prostate surgery for benign prostatic hyperplasia in Switzerland.

Authors:  Maria M Wertli; Brigitta Zumbrunn; Pascal Weber; Alan G Haynes; Radoslaw Panczak; Arnaud Chiolero; Nicolas Rodondi; Drahomir Aujesky
Journal:  PLoS One       Date:  2021-07-22       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.